Preparing for a New Era in Alzheimer's Disease: Debating New Targeted Biomarkers and Therapeutic Approaches : Episode 1
Opinion
Video
Apolipoprotein E4 in Alzheimer’s Disease
Author(s):
Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.
Video Player is loading.
Video content above is prompted by the following question(s):
- How are different stages of Alzheimer’s disease (AD; preclinical AD, prodromal AD, and AD with dementia) defined?
- What are known risk factors for Alzheimer's disease?
- Contribution of ApoE gene polymorphism and copy numbers
- When do patients with Alzheimer’s typically present to the clinic?
- What are known risk factors for Alzheimer's disease?
Related Videos
Management of Neurogenic Bladder
Exploring Multimodal Approaches to Neural Regeneration: Kuldip Dave, PhD
Insights into OPMD and Advancements in Genetic Research: Matthew Wicklund, MD
Bridging Neurology and Ophthalmology in Multiple Sclerosis Research
Challenges in Diagnosing Optic Neuritis in MS and MOGAD
Educating the Clinical Community on Changes to MS Diagnostic Criteria
HEALEY-ALS Platform Trial Amended, WVE-N531 Improves Muscle Growth in DMD, Diazoxide Choline Approved for Prader-Willi Syndrome
Impact of Optic Nerve Inclusion on Early MS Diagnosis and Treatment
Looking Ahead: Future Landscape for Treating OFF Time and Dyskinesia
Balancing Approved Therapies and Patient Preference in Parkinson Disease
Related Content
